Volume | 42 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Marker Therapeutics Inc | MRKR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
4.78 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
3 | 42 | - | 2.40 - 9.6799 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
07:32:43 | 25 | US$ 4.78 | USD |
Marker Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
42.49M | 8.89M | - | 3.31M | -8.24M | -0.93 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Marker Therapeutics News
Date | Time | Source | News Article |
---|---|---|---|
6/12/2024 | 15:05 | Edgar (US Regulatory) | Form 8-K - Current report |
5/17/2024 | 17:25 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of.. |
5/15/2024 | 15:40 | Edgar (US Regulatory) | Form 8-K - Current report |
5/15/2024 | 15:03 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
4/08/2024 | 06:00 | GlobeNewswire Inc. | Principal Investigator from City of Hope National Medical.. |
3/25/2024 | 16:45 | GlobeNewswire Inc. | Marker Therapeutics Reports Year-End 2023 Corporate and.. |
3/22/2024 | 11:30 | GlobeNewswire Inc. | Marker Therapeutics to Present at the H.C. Wainwright 2nd.. |
3/01/2024 | 07:02 | Edgar (US Regulatory) | Form 8-K - Current report |
2/26/2024 | 06:58 | Edgar (US Regulatory) | Form 8-K - Current report |
1/22/2024 | 06:30 | GlobeNewswire Inc. | Marker Therapeutics Receives Approval from United States.. |
1/08/2024 | 07:30 | Edgar (US Regulatory) | Form 8-K - Current report |
1/08/2024 | 07:24 | GlobeNewswire Inc. | Marker Therapeutics Announces Clinical Program Updates and.. |
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRKR Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.44 | 4.78 | 3.42 | 4.42 | 55,769 | 1.34 | 38.95% |
1 Month | 4.18 | 4.78 | 3.33 | 4.13 | 24,746 | 0.60 | 14.35% |
3 Months | 4.80 | 4.93 | 3.33 | 4.28 | 18,950 | -0.02 | -0.42% |
6 Months | 4.69 | 6.1568 | 3.33 | 4.45 | 22,950 | 0.09 | 1.92% |
1 Year | 3.13 | 9.6799 | 2.40 | 5.11 | 71,730 | 1.65 | 52.72% |
3 Years | 33.20 | 34.00 | 0.6706 | 7.44 | 475,668 | -28.42 | -85.60% |
5 Years | 61.80 | 91.70 | 0.6706 | 19.09 | 648,665 | -57.02 | -92.27% |
Marker Therapeutics Description
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. |